Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.83 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.83 |
| ▸ | USP7 | Q93009 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | STAT3 | P40763 | 1/20 | 0.83 |
| ▸ | CCR6 | P51684 | 1/20 | 0.74 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bardoxolone SCHEMBL14140295 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL7717241 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL92342 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL12447454 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL19236126 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL24337284 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL13569166 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL13827463 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL954253 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL16248344 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073321-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | UNIV NEW YORK (US) | 2025-03-06 | — | — | US | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| WO-2021062202-A1 | METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES | UNIVERSITY OF MASSACHUSETTS (US) | 2021-04-01 | — | — | WO | claimed |
| US-20210085763-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | NEW YORK UNIVERSITY | 2021-03-25 | — | — | US | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| EP-2991621-B1 | TWO-LAYER OCULAR IMPLANT | RETINA FOUND OF THE SOUTHWEST (US) | 2020-12-09 | — | — | EP | claimed |
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-11-05 | — | — | US | claimed |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2019-03-14 | — | — | US | claimed |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-01-08 | — | — | US | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| US-20170056373-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | SYRACUSE UNIVERSITY (US) | 2017-03-02 | — | — | US | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| EP-2991621-A2 | TWO-LAYER OCULAR IMPLANT | Odin Biotech (US) | 2016-03-09 | — | — | EP | claimed |
| US-20150133507-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2015-05-14 | — | — | US | claimed |
| WO-2014179568-A2 | TWO-LAYER OCULAR IMPLANT | ODIN BIOTECH (US) | 2014-11-06 | — | — | WO | claimed |
| EP-2793876-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | Ares Trading S.A. (CH) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092269-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | claimed |
| EP-4736949-A2 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20040002463-A1 | Inhibitors and methods of use thereof | THE TRUSTEES OF DARTMOUTH COLLEGE | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NOS2 1063/4885KEAP1 2/4885CYP3A4 4043/4885 |
| US-20150133507-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | NOS2 633/4885KEAP1 6/4885CYP3A4 299/4885 |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NOS2 1063/4885KEAP1 2/4885CYP3A4 4043/4885 |
| US-20040002463-A1 | Inhibitors and methods of use thereof | IRF3, MIF, IFNG | NOS2 10/4885KEAP1 952/4885CYP3A4 509/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NOS2 1063/4885KEAP1 2/4885CYP3A4 4043/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NOS2 1639/4885KEAP1 2/4885CYP3A4 3893/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NOS2 2389/4885KEAP1 2/4885CYP3A4 4408/4885 |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NOS2 1063/4885KEAP1 2/4885CYP3A4 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.